DGAP-News: Molecular Health GmbH: Molecular Health and FALCO biosystems team up to provide genetic analysis services using MH Guide/BRCA and MH Guide/Mendel PMS2, respectively. Therefore, testing BRCA1/2 genes and other heritable cancer-associated genes is becoming increasingly important: both to evaluate the affected patient's individual risk of developing cancer [1],[2], and as a predictive biomarker and companion diagnostic test for certain drugs [3]. Whereas MH Guide/BRCA detects variants in HBOC-associated genes, MH Guide/Mendel can analyze large gene panels as well as whole-exome or whole-genome data, so that many different hereditary diseases can be identified at once. "With this collaboration in place, Japanese patients will benefit from state-of-the-art genetic identification of inherited diseases like Hereditary Breast and Ovarian Cancer and many other diseases. This will allow sooner diagnosis and potentially earlier therapeutic intervention", said Christian Meisel, MD, PhD, Chief Medical Officer at Molecular Health.